the [Technical everyone. critical afternoon, crisis. Lynn the and of us. solid to I’m We pleased that to for Thanks, good attribute recovery indications we quarter trends COVID Thanks the continued day from first joining as report our third a had Difficulty]. to improve
can for and the creative well challenging I during I closing doubt past and financial to expectations can CFO remainder results I’ll quarters. helped review want devices greater our both pandemic. quarter on lives your color Then service Ashley their supply have remarks liquidity customer organization questions. in-person performance, throughout our virtually. many patients’ our procedures, QX as performance have have Additionally, will care. entire outstanding this over the also open XXXX. I incredible solutions that patient call their have They as and in times. team’s efforts employ Lee, they our dedication save proven no continued sincerely make thank to extraordinary They and these Today, resolve two ensure and up been will support these for third then our some provide the of to detail. and
results. through As advanced quarter, detail, on I key explain number our more the of solid will we in later a initiatives and third delivered
delayed at procedures reflects by our currency which fact Our be cannot third majority postponed was revenues of and driven that vast XXXX, the quarter revenue all, at that both we basis. long. quarter used are they the or of X% cannot million, performance GAAP versus in third of $XX.X In products constant be QX, decrease achieved very a for
total for the TMR XXXX, and exclude If quarters revenues decreased you of X% constant third revenues on a XXXX basis. currency
saw saw quarter second we quarter, of throughout volume. this the year, third in improving As procedure the we
managing These procedural belief, – In fact, and providers corroborate the at increasingly become the pandemic. over increased September have hospitals in continuity trends increased revenues XXXX, over XXXX. September our adept September during COVID-XX in
we to we could growth QX were XXXX. performance, to we look As return revenue optimistic versus that
U.S. situation and in inflection revenue fact, more Ireland the have a spikes of in recently in seen the and UK well October, seen is XXXX. as XXXX we’ve and XX% and was weeks, this In strong a lockdowns Europe. Europe, two pandemic as performance October our other past fluid countries rates Unfortunately, both and in
regulatory front and recently-launched our positive and Asia JOTEC that as the will optimistic beginning the we’ll NEXUS less in growth America, Pacific products; should into XXXX. next-generation or to continued QX, we as in are see we that return result, but benefit AMDS well to begin in we do from Latin anticipate a As that news benefit us, expansion on soon-to-be-launched
of AMDS We’re particularly result the as vision to Type hybrid Medical for of world’s acquisition the device elegant optimistic aligned A back arched acute modeling is on for used acquisition with own The technologically This we treatment with a aortic for now simple first AMDS. in our well aortic outlook the dissections, of of September. exceptionally most advanced, solutions patients Ascyrus provide our and disease. the which
for A on as AMDS acquisition, discussed become to care well the the complications As and as Ascyrus with A treatment believe the technology acute the we new dissections. which following of reoperations hospital improve standard-of-care reduce the with acute patient hemi-arch should repair Type the our Type reduce potential call aortic has the dissections, to costs. AMDS aortic has potential We added associated immediately
great We start. the a far, XXXX. $XXX,XXX a of was October, revenues over off October to increase month of for of XXX% approximately posted So we’re which
At any since Regarding our at with run three disruptions avoid continued it has to capacity continued place, been we disruptions. on or our and they’ve in supply any remain sites, work operations impact chain as fortunately, effective safety we’ve last and this believe if manufacturing facilities our in nothing very COVID-XX of changed our our and workforce. significant we update, of protocols each the earlier to year from the across home implemented few near minimizing
allowed in to past decision. procedures in continue our slowdown the previously, inventory to few improve has the us mentioned JOTEC As months
sewing assuming supplier remain year, on notified body the source our second worsening end the by in conducting a in considering of for the coming and also allow to don’t Europe, We inspection. preclude their or pandemic track have conditions
when growth remain investing we continuing strength now ahead, and a to by and of look mitigate position managing subsides. diligently, we operational pandemic risk strategically As expenses the in for our
in able projects. been make R&D on to initiatives significant progress strategic several we’ve fact, In
launches. continued JOTEC on First, we made progress product our
and we technologies. customer are market Our OPEN Open very And E-nside those E-vita positive the release for NEO NEO limited very today, feedback on progressing well. received
remain market also quarter, resumed track of E-nya limited to We have on launch already the for a and this release initiate limited NEXUS.
products in XXXX. early new We three JOTEC continue anticipate market full all release to for
train as build teams well As to up last supply mentioned on call, to the support as these three to in products. earnings market launches our our gear full physicians JOTEC are new continuing
QX seen QX, which maintained aortic up the if a year. have fully we to sites patients expect in solid in approximately to-date sites can target towards valve trial XX XX already X,XXX Second, Enrollment in to determine and patients On-X and progress enrollment and from QX enthusiastic. We next surgeons roll be over enrollment study warfarin. effectively Eliquis patients begin and the is been represents trial, ramped late our clinical that North in qualified and with XXA the with prospective, efforts currently to feedback very enrollment PROACT safely American patients’ randomized versus improvement the has – we’ve XX seen across participating the on our
meets As valve in we a FDA will its headwinds existing taking we contribute can valves. aortic result XXXX, and aortic in still achieve the believe segment, to from the market aortic endpoints, Eliquis assuming as valve pandemic share of for our well trial believe, as which the becoming approval bioprosthetic On-X the On-X valve use we progress despite mechanical with of leader
for to approval to year-end. FDA on quarter. first begin PMA U.S. their On the the will financials and the and remain also anticipates a the review enrolling quarter. Chinese BioGlue turn this to response U.S. to later NEXUS in to in PerClot finally, received our clinical that, for regulatory before front, the detailed patient we FDA file Endospan our call now With the our for track I for Ashley of and trial over
Ashley?
